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Aims: The endothelin (ET) system is a tissular system, as the production of ET isoforms is mostly autocrine or
paracrine. Macitentan is a novel dual ETA/ETB receptor antagonist with enhanced tissue distribution and
sustained receptor binding properties designed to achieve amore efﬁcacious ET receptor blockade. To determine
if these features translate into improved efﬁcacy in vivo, a studywas designed inwhich rats with either systemic
or pulmonary hypertension and equipped with telemetry were given macitentan on top of maximally effective
doses of another dual ETA/ETB receptor antagonist, bosentan, which does not display sustained receptor occupan-
cy and shows less tissue distribution.
Main methods: After establishing dose–response curves of both compounds in conscious, hypertensive Dahl salt-
sensitive and pulmonary hypertensive bleomycin-treated rats, macitentan was administered on top of the max-
imal effective dose of bosentan.
Key ﬁndings: In hypertensive rats,macitentan30 mg/kg further decreasedmean arterial bloodpressure (MAP) by
19mmHgwhen given on top of bosentan 100 mg/kg (n=9, p b 0.01 vs. vehicle). Conversely, bosentan given on
top of macitentan failed to induce an additional MAP decrease. In pulmonary hypertensive rats, macitentan
30 mg/kg further decreased mean pulmonary artery pressure (MPAP) by 4 mm Hg on top of bosentan (n= 8,
p b 0.01 vs. vehicle), whereas a maximal effective dose of bosentan given on top of macitentan did not cause
any additional MPAP decrease.
Signiﬁcance: The add-on effect of macitentan on top of bosentan in two pathological models conﬁrms that this
novel compound can achieve a superior blockade of ET receptors and provides evidence for greater maximal
efﬁcacy.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
Pulmonary arterial hypertension (PAH) is a severe disease caused by
constriction and remodeling of pulmonary vessels, progressing to right
heart failure and death (Voelkel et al., 2012). Until now, short-term
clinical trials in patientswith PAH showed that endothelin (ET) receptor
antagonists (ERAs) can improve exercise capacity, symptoms, cardio-
pulmonary hemodynamic variables, and delay time to clinical worsen-
ing (McLaughlin, 2011). A search for new ERAs with superior ET
receptor blockade – and better safety –was critical in order tomaximize
the potential to delay remodeling and disease progression.
Recently, the novel ERA macitentan (10 mg/day) showed a highly
signiﬁcant 45% reduction in the combined endpoint of morbidity and
mortality in a long-term Phase III clinical trial (SERAPHIN) in patientst, Actelion Pharmaceuticals Ltd,
.: +41 61 565 63 41; fax: +41
. This is an open access article undersuffering fromPAH (Pulido et al., 2013).Macitentan is a dual ETA/ETB re-
ceptor antagonist with increased tissue distribution and slow receptor
dissociation, resulting in sustained receptor occupancy time. In the
monocrotaline rat model of pulmonary hypertension, macitentan
prevented development of right ventricular hypertrophy and improved
survival (Bolli et al., 2012; Gatﬁeld et al., 2012; Iglarz et al., 2008). Slow
receptor dissociation minimizes competition between the ligand and
the drug at the target binding site and thus is a property that can im-
prove efﬁcacy of drugs (Swinney, 2006). Such an increased ability of
macitentan to block the ET receptors would be expected to achieve su-
perior efﬁcacy vs. ERAs with fast receptor dissociation kinetics, particu-
larly in pathological conditions in which the ET system is upregulated.
Macitentan also has an activemetabolite, a dual ETA/ETB receptor antag-
onist with a long half-life, ACT-132577, which likely contributes to the
pharmacological activity of macitentan (Iglarz et al., 2008).
To demonstrate that the improved physicochemical properties and
binding of macitentan could translate into superior pharmacological ac-
tivity, a study protocolwas designed that testedmacitentan's ability to in-
duce an additional decrease in blood pressure when administered on top
of the maximal effective dose of bosentan, another dual ETA/ETB ERA. Tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ .0/).3
Fig. 1. Scheme describing the ‘add-on’ protocol.
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were monitored in conscious, freely moving, systemic hypertensive,
Dahl salt-sensitive (DSS) rats and pulmonary hypertensive, bleomycin-
instilled Wistar rats, two pathological models associated with activated
ET-1 production (Park et al., 1997; Schiffrin, 2001).
Methods
Animals
Two-month-old DSS rats were purchased from Charles River (USA)
and two-month-old Wistar rats from Harlan (The Netherlands). All
rats were maintained under identical conditions in accordance with
the guidelines of the Swiss Animal Protection Law under licenses 164
and 185.
Transmitter implantation in DSS rats
In DSS rats, hypertension was induced and maintained by adminis-
tration of 1% NaCl in drinking water. Five to six weeks after starting
salt administration, a telemetry system (PA-C40, Data Sciences, St.
Paul, MN, USA) was implanted under anesthesia. In brief, a blood
pressure-sensing catheter was placed in the descending aorta below
the renal arteries, pointing upstream and implanted into the peritoneal
cavity to measure systemic arterial pressure (Brockway et al., 1991).
Transmitter implantation in bleomycin rats
Under sterile conditions, ventilated rats were instrumented micro-
surgically with a telemetry pressure transmitter implanted in the peri-
toneal cavity. The right ventricle was exposed using a right lateral
thoracotomy at the 6–7th intercostal space. A trench was made with a
stainless steel trocar from the peritoneal cavity to the thorax. The pres-
sure catheter was inserted into the ventricle to measure right ventricu-
lar pressure and further advanced through the pulmonary valve to
allow measurement of pulmonary pressure. The chest was closed and
the transmitter sutured to the abdominal musculature. Twenty-one
days after transmitter implantation, a single dose of bleomycin sulphate
(1.5 mg/kg/mL, Baxter AG, Volketswil, Switzerland followedby 1 mL/kg
of air, adapted fromWilliams et al., 1992)was intratracheally instilled in
each rat to induce mild pulmonary arterial hypertension.
Data acquisition by telemetry
Blood pressure was collected continuously using the Dataquest ART
Gold acquisition system (version 3.01). Systolic, mean and diastolic ar-
terial pressures and heart rate (HR) were collected at 5-min intervals
during the entire experiment, resulting in a series of 1152 data points
per day for each animal. For both blood pressure andHR, each rat served
as its own control, by using the data of the last 24 h before drug or vehi-
cle administration. An area between curves (ABC) was calculated for
mean arterial pressure (MAP) or mean pulmonary arterial pressure
(MPAP) vs. time curves of the control and treatment periods (integrated
differences between pre- and post-dose curves over time).
Dose–response curves and add-on protocol
First, dose–response curves of each ERA were constructed in both
systemic hypertensive DSS rats and bleomycin-induced pulmonary hy-
pertensive Wistar rats to determine the maximal effective dose and
Tmax (time of observed maximal effect) of each ERA. Pharmacological
effects on MAP or MPAP and HRwere measured up to 120 h after a sin-
gle gavage at doses ranging from 0.1 to 100 mg/kg (macitentan) or 3 to
600 mg/kg (bosentan). To determine whether macitentan could pro-
vide superior pharmacological activity vs. bosentan, we designed a
study in which: 1) macitentanwas administered on top of the maximaleffective dose of bosentan established by the dose–response curve as
shown in Figs. 1 and 2) the same dose of bosentan was administered
on top of the maximal effective dose of macitentan. The maximal effec-
tive dose of the second compoundwas administered at Tmax of the ﬁrst
tested compound.
Pharmacokinetics
In order to rule out any confounding drug–drug interaction on the
pharmacological effect measured, the exposure of macitentan and its
active metabolite ACT-132577 was measured in the presence or ab-
sence of bosentan in similar conditions to the add-on protocol. Vehicle
or bosentan 300 mg/kg was administered to Wistar rats (n = 6/
group) 6 h prior to macitentan 30 mg/kg. Plasma samples were collect-
ed at 1, 2, 3, 4, 6, 8 and 24 h after oral administration of macitentan,
and quantiﬁcation of macitentan and ACT-132577 was determined by
liquid chromatography coupled to mass spectrometry (API4000, AB
SCIEX, Concord, Ontario, Canada).
Test compounds
Macitentan and bosentan were supplied by Actelion Pharmaceuti-
cals Ltd. Gelatin 7.5%, administered at 5 mL/kg, was used as vehicle for
oral administration of the compounds by gavage.
Statistics
All results are presented asmean±SEM. Area between themean ar-
terial pressure vs. time curves (ABC) is expressed in mm Hg h, MAP or
MPAP in mmHg, and HR in bpm. Differences between groups were an-
alyzed using an unpaired Student t-test. Statistical signiﬁcance was de-
ﬁned as P 0.05.
Results
Determination of maximal effective doses in DSS rats and observation that
the maximal efﬁcacy of macitentan is greater than that of bosentan
DSS rats developed an increase in MAP up to approximately
180mmHg. MAP and HR baseline values were similar between the dif-
ferent experimental groups. After acute oral administration,macitentan
dose-dependently decreased MAP in DSS rats. The maximal effective
dose of macitentan was 30 mg/kg; this dose decreased MAP by 30 ±
5 mm Hg (Table 1). The maximal effect was reached at about 24 h
after administration (Tmax). Acute oral administration of bosentan
dose-dependently decreased MAP in DSS rats. At the maximal effective
dose of 100 mg/kg, bosentan decreased MAP by 15 ± 2 mm Hg
(Table 1), with a Tmax at 6 h. No effect on HR was observed. Based on
these data, the maximal effective doses of 30 mg/kg of macitentan and
100 mg/kg of bosentan were selected for the add-on study. Tmax was
determined to be 6 h for bosentan and 24 h for macitentan.
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Fig. 2. Superior pharmacological activity of macitentan vs. bosentan in Dahl-salt sensitive rats. Whereas addition of bosentan (Bos) 100 mg/kg on top of bosentan 100 mg/kg did not in-
duce further blood pressure reduction, addition of macitentan (Maci) 30 mg/kg on top of bosentan 100 mg/kg further decreased blood pressure by 19 mm Hg, **p= 0.004 vs. vehicle
(Vehi). Vehicle, second dose of macitentan 30 mg/kg or bosentan 100 mg/kg (arrow) was administered 6 h after the ﬁrst dose. n= 5–9/group. Data are expressed as mean ± SEM.
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bosentan using add-on protocol in DSS rats
The use of maximal effective doses of macitentan and bosentan was
conﬁrmed using the add-on protocol: macitentan 30 mg/kg adminis-
tered on top of macitentan 30 mg/kg did not cause an additional MAP
decrease as compared to vehicle on top of macitentan (−29 ± 2 and
−28 ± 5 mmHg). Bosentan 100 mg/kg, administered when the maxi-
mal effect of bosentan 100 mg/kg was reached, did not induce an addi-
tional MAP decrease compared to vehicle on top of bosentan (−13± 2
and−14 ± 3 mm Hg, respectively; Fig. 2).
Comparison between macitentan and bosentan using add-on protocol in
DSS rats
Oral administration of macitentan 30 mg/kg, when the maximal ef-
fect of bosentan 100 mg/kg had been reached, decreasedMAP by an ad-
ditional 19 mmHg compared to vehicle (p b 0.01) administered on top
of bosentan 100 mg/kg. The maximal decrease induced by macitentanwas 33 ± 4 mm Hg (Fig. 2). Conversely, bosentan, administered orally
at 100 mg/kg, when the maximal effect of macitentan 30 mg/kg had
been reached, did not induce an additional MAP decrease compared to
vehicle administered on top of macitentan 30 mg/kg (Fig. 3).
Determination of maximal effective doses in bleomycin-treated rats and
observation that the maximal efﬁcacy of macitentan is greater than that
of bosentan
Bleomycin-treated rats developed an increase in MPAP of approxi-
mately 13mmHg vs. saline-instilled rats. MPAP and HR baseline values
were similar between the different experimental groups. Acute oral ad-
ministration of macitentan and bosentan dose-dependently decreased
MPAP in bleomycin rats (Table 1) without affecting HR (data not
shown). At a dose of 30 mg/kg macitentan, the maximal decrease in
MPAP was 12 ± 3 mm Hg, about 24 h after administration (Tmax). At
the maximal effective dose of 300 mg/kg, bosentan decreased MPAP
by 7 ± 2 mm Hg (Table 1), with a Tmax around 6 h. Based on these
data, the maximal effective doses of 30 mg/kg of macitentan and
Table 1
Dose–response of macitentan and bosentan on blood pressure in DSS and bleomycin rats: maximal decreases and area between curves. MAP: mean arterial pressure, MPAP: mean pul-
monary arterial pressure, ABC: area between curves. Data are expressed as mean ± SEM.
Dose (mg/kg) 0.1 0.3 1 3 10 30 100 300 600
Dahl salt-sensitive hypertensive rats
Macitentan ΔMAP (mm Hg) −7 ± 5 −12 ± 4 −15 ± 2 −19 ± 3 −25 ± 3 −30 ± 5 −33 ± 6 – –
ΔABC (mm Hg h) −43 ± 37 −141 ± 38 −290 ± 44 −539 ± 98 −880 ± 160 −988 ± 159 −1714 ± 291 – –
Bosentan ΔMAP (mm Hg) – – – −6 ± 3 −8 ± 2 −8 ± 3 −15 ± 2 −13 ± 2 –
ΔABC (mm Hg h) – – – −21 ± 19 −68 ± 20 −44 ± 27 −209 ± 9 −285 ± 61 –
Bleomycin-induced pulmonary hypertensive Wistar rats
Macitentan ΔMPAP (mm Hg) – −5 ± 1 −7 ± 2 −8 ± 0 −12 ± 4 −12 ± 3 −10 ± 1 – –
ΔABC (mm Hg h) – −37 ± 14 −76 ± 18 −184 ± 35 −244 ± 58 −447 ± 104 −492 ± 60 – –
Bosentan ΔMPAP (mm Hg) – – – −5 ± 1 −6 ± 1 −8 ± 1 −5 ± 1 −7 ± 2 −6 ± 1
ΔABC (mm Hg h) – – – −31 ± 21 −58 ± 40 −77 ± 12 −64 ± 12 −97 ± 20 −80 ± 7
336 M. Iglarz et al. / Life Sciences 118 (2014) 333–339300 mg/kg of bosentan were selected for the add-on study. Tmax was
determined to be 6 h for bosentan and 24 h for macitentan.
Conﬁrmation of selection of maximal effective dose of bosentan using
add-on protocol in bleomycin-treated rats
The use of maximal effective doses of macitentan and bosentan was
conﬁrmed using the add-on protocol: macitentan 30 mg/kg adminis-
tered on top of macitentan 30 mg/kg did not cause an additional MPAP
decrease compared to vehicle on top of macitentan (−18 ± 2 and
−13 ± 2 mm Hg, p = 0.112). Similarly, as shown in Fig. 4, bosentan
300 mg/kg administered when the maximal effect of bosentan
300 mg/kg was reached did not cause an additional MPAP decrease
compared to vehicle on top of bosentan (−8 ± 1 and−7 ± 1 mm Hg,
respectively).
Comparison between macitentan and bosentan using add-on protocol in
bleomycin-treated rats
Oral administration of macitentan 30 mg/kg to bleomycin rats,
when the maximal effect of bosentan 300 mg/kg had been reached, in-
duced an additional MPAP decrease compared to vehicle administered0 24 48 72 96
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Fig. 3. Absence of pharmacological activity of bosentan on top of macitentan in conscious Dah
30 mg/kg did not induce further blood pressure reduction. Vehicle (Vehi) or bosentan dose
mean ± SEM.on top of bosentan 300 mg/kg. The maximal decrease induced by
macitentan on top of bosentanwas−11± 1mmHg (p b 0.01 vs. vehi-
cle) (Fig. 4). Conversely, bosentan, administered orally at 300 mg/kg,
when the maximal effect of macitentan 30 mg/kg had been reached,
did not induce an additional MPAP decrease compared to vehicle ad-
ministered on top of macitentan 30 mg/kg (Fig. 5).
Absence of drug–drug interaction
As shown in Fig. 6, administration of bosentan did not modify the
plasma concentrations of macitentan and its active metabolite ACT-
132577, ruling out a modiﬁcation of macitentan pharmacokinetics by
bosentan during the add-on protocol.
Discussion
Comparison of efﬁcacy between compounds is rarely assessed fairly
as it requires generating full dose–response curves in order to appropri-
ately compare maximal effects. In our study, dose–response curves
were established in conscious rats with either systemic or pulmonary
hypertension. We compared the maximal efﬁcacy of macitentan and
bosentan both in DSS rats and in the bleomycin rat model of PHMa
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Fig. 4. Superior pharmacological effect ofmacitentan on top of bosentan in conscious bleomycin-inducedpulmonaryhypertensive rats.While addition of bosentan (Bos) 300 mg/kg on top
of bosentan 300 mg/kg did not induce further mean pulmonary arterial pressure (MPAP) reduction, addition of macitentan (Maci) 30 mg/kg on top of bosentan 300 mg/kg further de-
creased blood pressure by 4 mm Hg, **p b 0.01 vs. vehicle (Vehi). Vehicle, second dose of bosentan 300 mg/kg or macitentan 30 mg/kg (arrow) was administered 6 h after the ﬁrst
dose of bosentan 300 mg/kg. n= 8/group. Data are expressed as mean ± SEM.
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develops rapidly progressing PH leading to death (Ryan et al., 2011;
Rey et al., 2012), bleomycin-treated rats develop a moderate but con-
stant and sustained increase in pulmonary pressure, which allows the
study of hemodynamics over a long period of time without dramatic
changes in MPAP (Williams et al., 1992). Macitentan achieved a superi-
or blood pressure reduction compared to bosentan in both animal
models:−30 ± 5 mm Hg vs.−15 ± 2 mm Hg on MAP, respectively,
in DSS rats, and−12 ± 3mmHg vs.−7± 2mmHg onMPAP, respec-
tively, in bleomycin rats. In addition to these results, we used an ‘add-
on’ protocol to conﬁrm and demonstrate the superior pharmacological
activity of macitentan vs. bosentan.
In both models, macitentan was able to induce a further blood
pressure reduction when given on top of the maximal efﬁcacious dose
of bosentan, whereas the opposite was not true, suggesting that
macitentan is able to block more efﬁciently ET receptors. In addition
ACT-132577, the active metabolite of macitentan, may contribute to
the superior activity of macitentan over bosentan. Indeed ACT-132577reaches higher plasma concentrations (Fig. 6) and has a prolonged
half-life compared to macitentan despite a lower potency than its
parent compound (Iglarz et al., 2008). The superior pharmacological
activity of macitentan cannot be explained by a change in selectivity
proﬁle towards ETA and ETB receptors as macitentan, ACT-132577
and bosentan, are all dual ERAs characterized by comparable ETA/ETB se-
lectivity ratios as determined in isolated organs (50:1, 16:1 and 22:1 for
macitentan, ACT-132577 and bosentan, respectively; Iglarz et al., 2008;
Clozel et al., 1994). Pharmacological efﬁcacy of a receptor antagonist de-
pends on its binding mode and afﬁnity to the receptor and the number
of receptors it can block in the target tissue (tissue distribution). Com-
bined optimization of these characteristics can also explain the superior
efﬁcacy of macitentan relative to bosentan.
Receptor binding mode differentiates macitentan from bosentan
Macitentan displays a slow receptor dissociation rate, as in pul-
monary arterial smooth muscle cells, the receptor occupancy half-life
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Fig. 5.Absence of pharmacological activity of bosentan on top ofmacitentan in conscious bleomycin rats. Addition of bosentan (Bos) 300 mg/kg on top ofmacitentan (Maci) 30 mg/kg did
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(Gatﬁeld et al., 2012). The slower dissociation kinetics of macitentan
translated into an insurmountable antagonism in studies of second
messenger signaling, whereas bosentan showed surmountable compet-
itive antagonism. As a result, macitentan inhibited the ET-1-induced
sustained elevation in intracellular calcium across the whole range of
ET-1 concentrations tested, which was not observed with bosentan.
DSS rats present high ET-1 plasma concentrations compared to normal
animals (Quaschning et al., 2001). High ET-1 plasma concentrations, as
a result of spillover of locally produced ET-1, reﬂect a saturation of tissue
receptors (Frelin andGuedin, 1994). Indeed, DSS andbleomycin-treated
rats show, respectively, increased cardiac and lung tissue production of
ET-1 (Mutsaers et al., 1998; Emoto et al., 2005). Therefore, in such con-
ditions of high local ET-1 concentrations, the slow receptor dissociation
rate ofmacitentanmight confer amore efﬁcient receptor blockade, con-
tributing to a more effective blood pressure reduction.
Tissue distribution differentiates macitentan from bosentan
Drug distribution in the target tissue is important to maximize the
number of receptors blocked. Macitentan's distribution coefﬁcient (logPl
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Fig. 6. Plasma concentrations of macitentan and its active metabolite ACT-132577 in the
presence of bosentan 300 mg/kg or vehicle. Vehicle or bosentan was administered 6 h
prior to macitentan 30 mg/kg. n= 6/group. Data are expressed as mean ± SD.D) favors partitioning to tissues and its pKa value corresponds to a
high fraction of the non-ionized form, able to cross cell membranes.
With a pKa of 6.2, 6% of macitentan is non-ionized in an aqueous envi-
ronment at physiological pH—a relatively high percentage compared
with 1% of bosentan. Macitentan shows a distribution of 800 to 1 be-
tween octanol and aqueous buffer, which predicts a good distribution
to lipids and tissues. In comparison, bosentan has a lower afﬁnity for
the lipophilic phase as shown by a distribution of 20 to 1 (Iglarz et al.,
2008).We recently reported that, usingmicroautoradiography analysis,
lung distribution of macitentan was greater than that of bosentan in
bleomycin-instilled rats (Iglarz et al., 2011). Thus, the improved physi-
cochemical properties of macitentan should favor its penetration in
the media and allow a more complete blockade of ET receptors than
bosentan. It might explain the additional effect of macitentan on top
of bosentan, as macitentan could engage receptors left unblocked after
dosing of bosentan.
Conclusion
In conclusion, our data demonstrate, using different approaches and
animal models, that macitentan is more efﬁcacious than bosentan
in vivo. Although bosentan has a similar mode of action (ETA and ETB
blockade), macitentan displays improved ability to achieve a more ef-
fective blockade of ET receptors via increased tissue distribution and
better receptor binding properties. This improved efﬁcacy may explain
the unique efﬁcacy of macitentan in reducing disease progression in pa-
tients with PAH as demonstrated in the SERAPHIN trial.
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